Novo Nordisk
800 Scudders Mill Rd
Plainsboro
NJ
08536
United States
Tel: (609) 987-5800
Website: http://www.novonordisk.com/
About Novo Nordisk
Novo Nordisk is the world's leading diabetes care company and the only company that provides a complete portfolio of insulin analog treatments and insulin delivery devices that respond to each stage of the diabetes life cycle. In addition, Novo Nordisk has a leading position in hemostasis management, growth hormone therapy and hormone therapy for women.
Vision
Novo Nordisk's ambition is to defeat diabetes, working as a catalyst to advance diabetes care through awareness, prevention, and education and to be at the forefront of research and development in other areas of healthcare where it can make a significant difference.
Triple Bottom Line
Novo Nordisk conducts its activities in a financially, environmentally, and socially responsible way as part of its underlying business principle, The Triple Bottom Line. This principle is the foundation of the Novo Nordisk Way of Management, which holds Novo Nordisk to the highest performance standards.
Novo Nordisk Highlights
• A heritage in diabetes care for more than 80 years • World's largest makers of insulin • More than 4,600 employees are engaged in research and development • In 2005, spent DKK 5,085 million in R & D • Operates manufacturing facilities in six nations, including the United States • Operates three research and development facilities worldwide (Denmark, US, China) • Rated as a healthcare leader on the global Dow Jones Sustainability World Index as well as the pan-European Dow Jones STOXX Sustainability Index (global recognition) • Named number one best place to work among large companies in NJ by NJBIZ magazine
Facts
• Global headquarters in Copenhagen, Denmark • US headquarters in Princeton, NJ • Employs an estimated 27,000 people in 81 countries • Markets its products in 179 countries • Employs 3900 people in the US • Insulin manufacturing facility in Clayton, NC
Financials
Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'.
Total sales in 2008 were: $8,935 million (DKK 45,553m) Net income-as reported in 2008: $1,892 million (DKK 9,645m) Earnings per share-as reported: $3.07(DKK 15.66) Dividends paid per share: $1.18(DKK 6.00)
History of Novo Nordisk
In the 1920s, two small Danish companies began producing insulin, which had just been discovered by a team of Canadian scientists. Nordisk Insulin laboratorium was founded in 1923.
A year later, Novo Terapeutisk Laboratorium was born, and began producing "Insulin Novo" and a special syringe. Over the decades, these two companies grew to be global leaders in insulin production. In January 1989, Novo and Nordisk decided to join forces to form a new company called Novo Nordisk A/S.
JOBS:
Please click here for Novo Nordisk job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
FOLLOW NOVO NORDISK:
Tweets by Novo Nordisk
1181 articles with Novo Nordisk
-
Researchers continue to explore how to turn deadly venom into life-saving drugs. Several papers on the subject have recently been published and BioSpace is taking a look at them.
-
In addition to lowering of blood sugar, Mounjaro also enabled patients to lower their weight by 15 to 23 pounds. The drug compared well to other diabetes medications including Novo Nordisk's semaglutide.
-
Flagship Pioneering has partnered with Novo Nordisk to build a portfolio of potential treatments for cardiometabolic and rare diseases.
-
The charges come from several in-process research and development projects acquired outside of a business combination.
-
The new bills result from a three-year investigation that honed in on anti-competitive efforts that have prevented generic drugs and biosimilars from entering the market.
-
Novo Nordisk receives FDA approval of higher-dose Ozempic® 2 mg providing increased glycemic control for adults with type 2 diabetes
3/28/2022
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a 2 mg dose of Ozempic® (semaglutide) injection, a once-weekly glucagon-like peptide-1 (GLP-1) analog indicated along with diet and exercise to improve blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease.
-
First Moscow State Medical University has paused recruiting new patients for its ongoing clinical trials following a disruption in the university’s ability to receive clinical trial samples.
-
Evotec entered into a drug discovery collaboration for metabolic diseases with Eli Lilly, focusing on kidney disease and diabetes.
-
The Danish pharma giant is partnering with EraCal Therapeutics, to develop new obesity-related drug targets.
-
Cardiometabolic disease is an overlooked therapeutic space that represents a huge and growing need as the global population ages, according to panelists speaking at Biotech Showcase.
-
As 2022 gets underway, multiple companies have already announced partnerships that will advance the potential for new medications in various disease indications.
-
On December 28, the U.S. Food and Drug Administration reported there had been 50 novel drug approvals for the year, and that was just for new chemical entities.
-
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
12/28/2021
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed.
-
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna
12/25/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, 2021.
-
Biopharma companies are eying the establishment of new facilities across the globe that will bolster their manufacturing strategies. BioSpace rounds up some of the latest announcements.
-
Novo Nordisk to Acquire Dicerna
11/18/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna.
-
Novo Nordisk and Dicerna are no strangers. The companies have been collaborating on the development of RNAi therapies for liver disease for the past three years.
-
Two weeks after Novartis announced it would sell its nearly one-third voting stake in next-door neighbor Roche, investors are chomping at the bit to find out how that almost $21 billion will be put to work.
-
Research into Alzheimer’s disease is shifting from amyloid plaque and tau protein to neuroinflammation, white matter changes and insulin resistance.
-
Cell and gene therapies are at an inflection point, as increasing quantities of clinical data highlight both their potential and their challenges.